Prodrugs for phosphorus-containing compounds

Details Prodrugs for phosphorus-containing compounds Prodrugs for phosphorus-containing compounds

2008-04-01

2008-04-01

Jones, Dameron L. (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C514S007600, C549S200000, C568S008000

Reexamination Certificate

active

11145194

ABSTRACT:
Prodrugs of formula I, their uses, their intermediates, and their method of manufacture are described:and pharmaceutically acceptable prodrugs and salts thereof.

REFERENCES:
patent: 3018302 (1962-01-01), Bielefeld et al.
patent: 4952740 (1990-08-01), Juge et al.
patent: 5130303 (1992-07-01), Akiyama et al.
patent: 5658889 (1997-08-01), Gruber et al.
patent: 5663159 (1997-09-01), Starrett, Jr. et al.
patent: 5962522 (1999-10-01), Wacher et al.
patent: 6004927 (1999-12-01), Benet et al.
patent: 6028054 (2000-02-01), Benet et al.
patent: 6054587 (2000-04-01), Reddy et al.
patent: 6110903 (2000-08-01), Kasibhatla et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6294672 (2001-09-01), Reddy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6399782 (2002-06-01), Kasibhatla et al.
patent: 6489476 (2002-12-01), Dang et al.
patent: 6752981 (2004-06-01), Erion et al.
patent: 6946115 (2005-09-01), Erion et al.
patent: 2003/0225277 (2003-12-01), Kopcho et al.
patent: 2003/0229225 (2003-12-01), Reddy et al.
patent: 2004/0092476 (2004-05-01), Boyer et al.
patent: 2004/0192651 (2004-09-01), Reddy et al.
patent: 2005/0101775 (2005-05-01), Erion et al.
patent: 2005/0282782 (2005-12-01), Martin
patent: 3 512 781 (1985-04-01), None
patent: 0 161 955 (1985-11-01), None
patent: 0 180 276 (1986-07-01), None
patent: 0 338 372 (1989-10-01), None
patent: 0 353 692 (1990-02-01), None
patent: 0 481 214 (1992-04-01), None
patent: WO 90/08155 (1990-07-01), None
patent: WO 90/09163 (1990-08-01), None
patent: WO 90/10636 (1990-09-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 96/01267 (1996-01-01), None
patent: WO 97/03679 (1997-02-01), None
patent: WO 98/09668 (1998-03-01), None
patent: WO 98/39342 (1998-09-01), None
patent: WO 98/39343 (1998-09-01), None
patent: WO 98/39344 (1998-09-01), None
patent: WO 99/47549 (1999-09-01), None
patent: WO 00/14095 (2000-03-01), None
patent: WO 00/38666 (2000-07-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 01/18013 (2001-03-01), None
patent: WO 02/00673 (2002-01-01), None
patent: WO 03/095665 (2003-11-01), None
patent: WO 2004/037161 (2004-05-01), None
patent: WO 2004/041834 (2004-05-01), None
patent: WO 2004/041837 (2004-05-01), None
Ayral-Kaloustian, S., et al., “Synthesis of Partially-Protected D-Frutofuranoses and D-Fructose-6-Phosphates”,Carbohydrate Research214: 187-192, Elsevier Science Publishers B.V., Amsterdam (1991).
Bentrude, Wesley G., et al. “Conformation of Saturated Six-Membered-Ring Phosphorus Heterocycles. 2-Aryl-1,3,2λ5-oxazapphosphorinanes”J. Am. Chem Soc.110: 7119-7127 (1988).
Bentrude, Wesley G., et al. “Conformations of Saturated Six-Membered-Ring Phosphorus Heterocycles Related to Cyclophosphamide. NMR, X-ray, and Infrared Studies of 2-Methoxy-2-oxo-1,3,2-oxazaphosphorinane and 2-Thio-1,3,2-oxazaphosphorinane”J. Am. Chem Soc.108: 6696-6675 (1986).
Denmark, Scott E., et al., “Asymmetric Electrophilic Amination of Chiral Phosphorus-Stabilized Anions”Tetrahedron48/11: 2191-2208 Pergamon Press plc (1992).
Erion, M., et al., “Liver-Targeted Drug Delivery Using HepDirect Prodrugs”J. Pharmacol. Exper. Ther. 312:554-560, American Society for Pharmacology and Experimental Therapeutics (Feb. 2005).
Erion, M. et al. “HepDirect Prodrugs for Targeting Nucleotide-Based Antiviral Drugs to the Liver”Current Opinion in Investigational Drugs7/2:109-117, The Thomson Corporation (2006).
Erion, M., et al., “Design, Synthesis, and Characterization of a Series of Cytochrome P4503A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver,”J. Am. Chem. Soc. 126:5154-5163, American Chemical Society (Apr. 2004).
Fang, C., et al. “Liver-Targeting Prodrug of PMEA Induces a Much More Favorable Kidney and Liver Toxicological Gene Expression-in Rats Compared to BisPOM-PMEA” Abstract #1274, 42ndAnnual Meeting of the Society of Toxicology, Salt Lake City, UT (Mar. 9-13, 2003).
Fang, C., et al., “Renal Toxicological Gene Response to Anti-Hepatitis B Prodrugs Hepavir B and Hepsera in Rats” Abstract #1472, 43rdAnnual Meeting of the Society of Toxicology, Baltimore, MD (Mar. 21-25, 2004).
Freeman, Sally, et al., “Prodrug Design for Phosphates and Phosphonates” Chapter 3 inProgress in Medicinal Chemistry, 34 111-147 Elsevier Sciences BV (1997).
Hong, Z. and Lin, C.-C., “Clinical Update of Remofovir (Hepavir B): a Liver-targeting Prodrug of PMEA for the Treatment of Hepatitis B,” Presented at theSRI-Antiviral Drug Discovery&Development Summit, Mar. 30, 2004.
Hong, Z., “Hepavir B: a Safer and Liver-Targeting Prodrug of PMEA,” Presented at theSRI-Antiviral Drug Discovery&Development Summit, Ribopharm Inc., Mar. 27, 2003.
Lin, C.-C., et al. “Comparative Disposition and Metabolic Profiles of [14C]Remofovir and [14C]Adefovir Dipivoxil in Rat Liver and Kidney” Abstracts of the 40thAnnual Meeting of the European Association for the Study of the Liver, Paris, France,J. Hepatology42/2 Abstract #405 Elsevier (Apr. 2005).
Lin, C.-C., et al. “Single-Dose Pharmacokinetics and Metabolism of [14C]Remofovir in Rats and Cynomolgus Monkeys”Antimicrobial Agents and Chemotherapy49/3: 925-930, American Society for Microbiology (Mar. 2005).
Lin, C.-C., et al., “Pradefovir is a Substrate, but Neither an Inhibitor nor an Inducer for Cytochrome P450,” AASLD Abstracts,Hepatology514A:Abstract No. 811, John Wiley & Sons, Inc. (Oct. 2005).
Lin, C.-C., et al., “Remofovir Mesylate: a Prodrug of PMEA with Improved LIver-Targeting and Safety in Rats and Monkeys,”Antiviral Chem. Chemother. 15:307-316, International Medical Press (2004).
Mackenna, D., et al., “MB07133: A HepDirect™ Prodrug of Cytarabine Monophosphate for Use in Hepatocellular Carcinoma,”Hepatology 38(Suppl. 1):411A, AASLD Abstract No. 524, John Wiley & Sons, Inc. (Oct. 2003).
Meier, Chris, et al. “ADA-Bypass by Lipophilic CycloSal-ddAMP Pro-Nucleotides. A Second Example of the Efficiency of the cycloSal-Concept”Bioorganic&Medicinal Chemistry Letters7/12: 1577-1582 Elsevier Science Ltd. (1997).
Reddy, K.R., et al., “Stereoselective Synthesis of Nucleoside Monophosphate HepDirect™ Prodrugs,”Tetrahedron Lett. 46:4321-4324, Elsevier Ltd. (2005).
Reddy, M.R. et al., Development of a Quantum Mechanics-Based Free-Energy Perturbation Method: Use in the Calculation of Relative Solvation Free Energies,J. Am. Chem. Soc.126, 6224-6225 (2004).
Shih, Y-E, et al. Studies on Potential Antitumor Agents (III). Synthesis of 4-Arylcyclophosphamides.Heterocycles9/9 1277-1285 (1978).
Ten Hoeve, W. and Wynberg, H. “The Design of Resolving Agents. Chiral Cyclic Phosphoric Acids”J. Org. Chem.50: 4508-4514, American Chemical Society (1985).
Vitarella, D. et al. “Hepavir B, A CYP3A4-Activated Prodrug of PMEA, Showed Better Safety then Hepsera in Pre-Clinical Studies” Abstract #995 of the 43rdAnnual Meeting of the Society of Toxicology, Baltimore, MD (Mar. 2004).
Xu, C.R., et al., “Toxicokinetics of Remofovir in Mice, Rats and Monkeys After Repeated Oral Administrations” Abstract #PB-P008 of the 64thInternational Congress FIP World Congress of Pharmacy and Pharmaceutical Science, New Orleans, LA (Sep. 2004).
Xu, C.R., et al. “Toxicokinetics of Adefovir Dipivoxil and Remofovir in 28-Day Toxicity Studies” Abstract #PB-P009 of the 64thInternational Congress FIP World Congress of Pharmacy and Pharmaceutical Science, New Orleans, LA (Sep. 2004).
Alexander, P., et al., “Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs,”Collect. Czech. Chem. Commun. 59:1853-1869, Nakladatelstvi Ceskoslovenski Akademie Ved. (1994).
Amin, D., et al., “1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic Acid as a Potent Inhibitor of Squalene Synthase,”Arzneim.-Forsch/Drug Res. 46:759-762, Black

Affiliated with

Also associated with

Rating

Prodrugs for phosphorus-containing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs for phosphorus-containing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs for phosphorus-containing compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3926943